All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
More than three times as many transplant recipients with confirmed resistant cytomegalovirus (CMV) infection at baseline receiving the investigational drug Maribavir achieved cmv viremia clearance compared to conventional antiviral therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2021
Details:
Japan has approved Avigan, known generically as favipiravir, as an emergency flu medicine. But concerns remain, as the drug has been shown to cause birth defects in animal studies and its effectiveness against COVID-19 has proven difficult to demonstrate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation but failed to demonstrate statistically significant results in reducing mortality among those with mild to moderate COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
More than twice as many transplant recipients with R/R CMV infection/disease treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8, the study’s primary endpoint, as compared to 23.9% of those on conventional antiviral therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Details:
Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection met its primary endpoint.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Camostat
Therapeutic Area: Infections and Infectious Diseases Product Name: Foipan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Foipan® Tablets is an oral protease enzyme inhibitor created internally at ONO, and obtained a manufacturing and marketing approval in 1985 for the alleviation of acute symptoms associated with chronic pancreatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Government of Japan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 29, 2020
Details:
Under the terms of the new agreement with the MHLW and Moderna, Takeda will be responsible for securing the necessary regulatory approvals prior to distributing 50 million doses of Moderna’s COVID-19 vaccine candidate in Japan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
FUJIFILM conducted a phase III trial in Japan for COVID-19 patients with non-severe pneumonia. Based on the results, it seeks to add, indication as well as dosage and administration concerning COVID-19 to the current manufacturing and marketing approval items of Avigan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: No
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
